Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTNNB1 | P35222 | 3/20 | 0.38 |
| ▸ | WNT3A | P56704 | 3/20 | 0.38 |
| ▸ | ACHE | P22303 | 7/20 | 0.37 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.33 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.33 |
| ▸ | BCHE | P06276 | 4/20 | 0.33 |
| ▸ | PTGES2 | Q9H7Z7 | 2/20 | 0.33 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4853757 | 0.95 | PTGS1 (0.37) | CTNNB1WNT3AACHEPTGS1PTGS2 | |
| SCHEMBL5313267 | 0.95 | ACHE (0.38) | CTNNB1WNT3AACHEPTGS1PTGS2 | |
| SCHEMBL13987199 | 0.92 | CTNNB1 (0.38) | CTNNB1WNT3AACHEPTGS1PTGS2 | |
| SCHEMBL4858812 | 0.92 | CTNNB1 (0.40) | CTNNB1WNT3AACHEPTGS1PTGS2 | |
| SCHEMBL4853308 | 0.90 | PTGS1 (0.33) | CTNNB1WNT3APTGS1PTGS2 | |
| SCHEMBL13987725 | 0.89 | CTNNB1 (0.41) | CTNNB1WNT3AACHEBCHEPTGES2 | |
| SCHEMBL4855046 | 0.89 | CTNNB1 (0.39) | CTNNB1WNT3AACHEBCHEPTGES2 | |
| Hydrochloric Acid SCHEMBL4860416 | 0.88 | CTNNB1 (0.41) | CTNNB1WNT3AACHEBCHEPTGES2 | |
| SCHEMBL5329226 | 0.88 | ACHE (0.37) | ACHEBCHEPTGES2CHRM2CHRM1 | |
| SCHEMBL5312226 | 0.87 | PTGS1 (0.36) | PTGS1PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7462628-B2 | Preventives/remedies for urinary disturbance | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-12-09 | — | — | US | disclosed |
| US-7138533-B2 | Preventives/remedies for urinary disturbance | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-11-21 | — | — | US | disclosed |
| US-7132547-B2 | Preventives/remedies for urinary disturbance | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-11-07 | — | — | US | disclosed |
| US-20060211675-A1 | Preventives/remedies for urinary disturbance | ISHIHARA YUJI | 2006-09-21 | — | — | US | disclosed |
| US-20060063769-A1 | Preventives/remedies for urinary disturbance | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-03-23 | — | — | US | disclosed |
| US-20050197362-A1 | Preventives/remedies for urinary disturbance | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-09-08 | — | — | US | disclosed |
| EP-1466625-A1 | PREVENTIVES/REMEDIES FOR URINARY DISTURBANCE | Takeda Chemical Industries, Ltd. (JP) | 2004-10-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060063769-A1 | Preventives/remedies for urinary disturbance | ACHE, BPHL, CHRM1 | CTNNB1 2598/4885WNT3A 3076/4885ACHE 1/4885 |
| US-20050197362-A1 | Preventives/remedies for urinary disturbance | ACHE, BPHL, CHRM1 | CTNNB1 2598/4885WNT3A 3076/4885ACHE 1/4885 |
| US-20060211675-A1 | Preventives/remedies for urinary disturbance | ACHE, BPHL, ACE | CTNNB1 4153/4885WNT3A 4058/4885ACHE 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.